

CITATION REPORT

List of articles citing

Circulatory function and hepatorenal syndrome in cirrhosis

DOI: 10.1002/hep.20766
Hepatology, 2005, 42, 439-47.

Source: <https://exaly.com/paper-pdf/38329904/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
498	Hepatorenal syndrome--is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?. <i>Hepatology</i> , 2005 , 42, 263-5	11.2	30
497	The endocannabinoid system in chronic liver disease. <i>Annals of Hepatology</i> , 2005 , 4, 248-254	3.1	15
496	Yearbook of Intensive Care and Emergency Medicine. <i>Yearbook of Intensive Care and Emergency Medicine</i> , 2006 ,		2
495	Therapy insight: Cirrhotic cardiomyopathy. 2006 , 3, 329-37		101
494	Hepatorenal syndrome. <i>Clinics in Liver Disease</i> , 2006 , 10, 371-85, ix-x	4.6	15
493	La prise en charge du syndrome hépatorenal en réanimation. 2006 , 10, 353-358		
492	Cardiac electrophysiological abnormalities in patients with cirrhosis. 2006 , 44, 994-1002		118
491	Cirrhotic Cardiomyopathy: Concise Review. <i>Annals of Hepatology</i> , 2006 , 5, 132-139	3.1	24
490	Terlipressin for hepatorenal syndrome. 2006 , CD005162		19
489	The management of severe alcoholic liver disease and variceal bleeding in the intensive care unit. 2006 , 12, 171-7		2
488	Portal hypertension. 2006 , 22, 254-62		6
487	The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. <i>Hepatology</i> , 2006 , 43, S121-31	11.2	420
486	Liver failure and liver disease. <i>Hepatology</i> , 2006 , 43, S239-42	11.2	13
485	The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. <i>Hepatology</i> , 2006 , 43, 385-94	11.2	105
484	Impaired 11 beta-hydroxysteroid dehydrogenase contributes to renal sodium avidity in cirrhosis: hypothesis or fact?. <i>Hepatology</i> , 2006 , 44, 795-801	11.2	21
483	Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006 , 44, 1535-42	11.2	268
482	New treatments of hepatorenal syndrome. 2006 , 26, 254-64		29

481	Hepatorenal syndrome: pathophysiology and management. 2006 , 1, 1066-79	166
480	Intensive Care Medicine. 2006 ,	
479	Therapy insight: Management of hepatorenal syndrome. 2006 , 3, 338-48	20
478	Sodium in Health and Disease. 2007 ,	3
477	The liver and the kidney: mutual clearance or mixed intoxication. 2007 , 156, 17-23	3
476	Cardiovascular determinants of survival in cirrhosis. 2007 , 56, 746-8	22
475	Retinoids, bile acids and PPARs in Barrett's oesophagus. 2008 , 57, 137	0
474	Splanchnic and systemic vasodilatation: the patient. 2007 , 41 Suppl 3, S266-71	17
473	Hemodynamic evaluation before liver transplantation: insights into the portal hypertensive syndrome. 2007 , 41 Suppl 3, S323-9	24
472	Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. 2007 , 46, 935-46	108
471	Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. 2007 , 47, 499-505	229
470	Syndrom hēpatorenal. 2007 , 197-220	
469	L'insuffisance rēnale aiguē 2007 ,	
468	Syndrom hēpatorenal : prēvention et traitement. 2007 , 16, 605-611	
467	Syndrom hepatorenal. 2007 , 28, 150-157	
466	[Hepatorenal syndrome]. 2007 , 30, 548-54	1
465	Cirrhotic cardiomyopathy. 2007 , 2, 15	74
464	Pathogenesis, Diagnosis and Treatment of Ascites in Cirrhosis. 666-710	1

463	Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. 2007 , 133, 818-24		494
462	Hepatorenal syndrome. <i>World Journal of Gastroenterology</i> , 2007 , 13, 4046-55	5.6	7
461	The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece?. <i>Hepatology</i> , 2007 , 46, 943-6	11.2	11
460	The patient with refractory ascites. 2007 , 21, 551-60		12
459	Review article: Management of ascites and associated complications in patients with cirrhosis. 2007 , 26 Suppl 2, 183-93		71
458	Albumin infusion fails to restore circulatory function following paracentesis of tense ascites as assessed by beat-to-beat haemodynamic measurements. 2008 , 62, 1851-7		5
457	Cardiac dysfunction in cirrhosis. 2007 , 21, 125-40		82
456	Hepatorenal syndrome: current management. 2008 , 10, 22-9		9
455	Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. 2008 , 25, 1105-40		43
454	Pathogenetic background for treatment of ascites and hepatorenal syndrome. 2008 , 2, 416-28		37
453	Haemodynamic effects of plasma-expansion with hyperoncotic albumin in cirrhotic patients with renal failure: a prospective interventional study. 2008 , 8, 39		16
452	Molecular adsorbents recirculating system (MARS) and the failing liver: a negative editorial for a positive trial?. <i>Hepatology</i> , 2008 , 47, 2143-4	11.2	2
451	An abnormal gene expression of the beta-adrenergic system contributes to the pathogenesis of cardiomyopathy in cirrhotic rats. <i>Hepatology</i> , 2008 , 48, 1913-23	11.2	25
450	Acute kidney injury in cirrhosis. <i>Hepatology</i> , 2008 , 48, 2064-77	11.2	429
449	[Dilutional hyponatremia, hepatorenal syndrome and liver transplantation]. 2008 , 31, 29-36		0
448	Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. 2008 , 134, 1352-9		414
447	Portal hypertension and its complications. 2008 , 134, 1715-28		256
446	Fisiopatología de la ascitis y del síndrome hepatorenal en la cirrosis. 2008 , 7, 1-5		

445	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. 2007 , 56, 1310-8	323
444	The hepatorenal syndrome. 2008 , 92, 813-37, viii-ix	35
443	Diagnosis and Management of Liver Failure in the Adult. 2008 , 1577-1604	
442	Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. 2008 , 48 Suppl 1, S93-103	75
441	Cardiovascular complications of cirrhosis. 2008 , 57, 268-78	262
440	Fluid retention in cirrhosis: pathophysiology and management. 2008 , 101, 71-85	54
439	Acute kidney injury: new concepts. Hepatorenal syndrome: the role of vasopressors. 2008 , 109, p73-9	22
438	Pathogenesis and Clinical Practice in Gastroenterology. 2008 ,	
437	Vagal mediation of systemic cardiovascular response to portal hypertension: from experimental studies in animals to treatment of humans. 2008 , 57, 884-5	3
436	The management of ascites and hyponatremia in cirrhosis. 2008 , 28, 43-58	66
435	Pathogenesis and treatment of hepatorenal syndrome. 2008 , 28, 81-95	128
434	Renal dysfunction in patients with chronic liver disease. 2009 , 7, 42-50	5
433	Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?. 2009 , 2, 370-6	81
432	Treatment of hepatorenal syndrome. 2009 , 29, 1196-211	20
431	Severe sepsis in cirrhosis. <i>Hepatology</i> , 2009 , 50, 2022-33	11.2 313
430	Cirrhotic cardiomyopathy. 2009 , 3, 294-304	130
429	Increased plasma nitric oxide, L-arginine, and arginase-1 in cirrhotic patients with progressive renal dysfunction. 2009 , 24, 1030-7	16
428	Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome. 2009 , 24, 1707-9	2

427	The heart and the liver. 2009 , 3, 51-64		38
426	The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2458-66	0.7	129
425	Renal failure in patients with cirrhosis. 2009 , 93, 855-69, viii		28
424	Ascites: pathogenesis and therapeutic principles. 2009 , 44, 902-11		35
423	Renal failure in cirrhosis. 2009 , 361, 1279-90		571
422	[Hepatorenal syndrome]. 2009 , 5, 150-6		
421	Le syndrome h�pator�nal. 2009 , 13, 262-272		
420	Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. 2009 , 43, 680-5		96
419	Renal failure in patients with cirrhosis: hepatorenal syndrome and renal support strategies. 2010 , 23, 139-44		18
418	Perioperative considerations in patients with cirrhotic cardiomyopathy. 2010 , 23, 128-32		15
417	BNP as marker of heart dysfunction in patients with liver cirrhosis. 2010 , 22, 1331-6		17
416	Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. 2010 , 22, 1085-92		54
415	Balancing volume resuscitation and ascites management in cirrhosis. 2010 , 23, 151-8		14
414	Cardiorenal Syndrome [A New Entity?]. 2010 , 102-111		5
413	TIPS for HRS. 2010 , 142-148		
412	Hepatorenal Syndrome. 2010 , 21, 165-184		
411	Novel Definition of Hepatorenal Syndrome: Clinical Consequences. 2010 , 122-129		2
410	Terlipressin for Hepatorenal Syndrome: The US Experience. 2010 , 163-171		

409	Managing hyponatremia in cirrhosis. 2010 , 5 Suppl 3, S8-17		3
408	Das hepatorenale Syndrom. 2010 , 5, 29-42		
407	Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. <i>Hepatology</i> , 2010 , 52, 1017-22	11.2	337
406	Beta-blockers in cirrhosis: friend and foe?. <i>Hepatology</i> , 2010 , 52, 811-3	11.2	31
405	Effects of TIPS on global end-diastolic volume and cardiac output and renal resistive index in ICU patients with advanced alcoholic cirrhosis. <i>Annals of Hepatology</i> , 2010 , 9, 40-45	3.1	13
404	Portal Hypertension. 2010 , 125-143		
403	Hepatorenal syndrome: beyond liver failure. 2010 , 21, 165-86		3
402	Hepatorenal Syndrome. 2010 , 858-867		
401	Effects of a single dose of terlipressin on transcutaneous oxygen pressures. 2010 , 45, 953-8		4
400	Síndrome hepatorenal: patogénesis y tratamiento. 2010 , 21, 613-622		
399	Das hepatorenale Syndrom. 2010 , 6, 41-52		1
398	Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. 2010 , 8, 616-22; quiz e80		69
397	Hepatorenal syndrome: a comprehensive overview for the critical care nurse. 2010 , 22, 351-68		1
396	Cirrhotic cardiomyopathy. 2010 , 56, 539-49		222
395	Cirrhotic cardiomyopathy. 2010 , 53, 179-90		234
394	Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. 2010 , 53, 1135-45		83
393	[Chronic liver failure: a clinical entity in need of researchers]. 2010 , 33, 619-20		0
392	Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. 2010 , 59, 105-10		235

391	Renal Complications of Liver Disease and the Hepatorenal Syndrome. 2011 , 362-380		
390	Hepatorenal syndrome: do the vasoconstrictors work?. 2011 , 40, 581-98		4
389	Hepatorenal syndrome. 2011 , 12, 1405-17		17
388	Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. 2011 , 5, 523-37; quiz 537		71
387	Management of hepatorenal syndrome in patients with cirrhosis. 2011 , 7, 517-26		47
386	Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. 2011 , 60, 702-9		282
385	Hepatorenal syndrome. 2011 , 174, 46-55		15
384	Chronic Liver Failure. 2011 ,		2
383	The heart in liver transplantation. 2011 , 54, 810-22		66
382	Eblockers and refractory ascites in cirrhosis: the message of a team of true scientists. 2011 , 55, 743-4		5
381	Cystatin C level as a predictor of death and cardiovascular events after liver transplantation. 2011 , 43, 732-4		5
380	Gastrointestinal Structure and Function. 2011 , 1207-1220		1
379	Pathophysiological basis of albumin use in cirrhosis. <i>Annals of Hepatology</i> , 2011 , 10, S6-S14	3.1	24
378	Anatomical cardiac alterations in liver cirrhosis: An autopsy study. <i>Annals of Hepatology</i> , 2011 , 10, 321-326		31
377	Prognostic Markers in Patients with Ascites and Hepatorenal Syndrome. 2011 , 31, 139-146		2
376	Ascites. 2011 , 210-233		2
375	Terlipressin in hepatorenal syndrome: Evidence for present indications. 2011 , 26 Suppl 1, 109-14		28
374	A perspective on cirrhotic cardiomyopathy. 2011 , 43, 1649-53		33

373	Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials. 2011 , 58, 928-38		69
372	[Perioperative anesthesia management of extended partial liver resection. Pathophysiology of hepatic diseases and functional signs of hepatic failure]. 2011 , 60, 103-17		7
371	EBlocker bei Leberzirrhose mit Aszites. 2011 , 6, 323-324		
370	Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites?. <i>Hepatology</i> , 2011 , 53, 370-1	11.2	11
369	Drug-induced autoimmune hepatitis: an easily reversible type of liver fibrosis?. <i>Hepatology</i> , 2011 , 53, 370	11.2	3
368	Tea intake and liver diseases. <i>Hepatology</i> , 2011 , 53, 373-4	11.2	1
367	Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2011 , 53, 372-3	11.2	12
366	The deleterious effects of propranolol on patients with cirrhosis. <i>Hepatology</i> , 2011 , 53, 371-2	11.2	3
365	Hepatectomy versus radiofrequency ablation for early-stage hepatocellular carcinoma. <i>Hepatology</i> , 2011 , 53, 374	11.2	1
364	Combinative strategy using tamoxifen and other chemotherapeutic drugs for cholangiocarcinoma chemotherapy. <i>Hepatology</i> , 2011 , 53, 375-6	11.2	1
363	Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. <i>Hepatology</i> , 2011 , 53, 375	11.2	11
362	Linkage of the hepatitis C virus genotype and interleukin-28B genetic polymorphisms in Asian patients. <i>Hepatology</i> , 2011 , 53, 367-8; author reply 368	11.2	13
361	Reply:. <i>Hepatology</i> , 2011 , 53, 368-368	11.2	
360	Hyponatremia in patients treated with terlipressin: mechanisms and implications for clinical practice. <i>Hepatology</i> , 2011 , 53, 368-9; author reply 369-70	11.2	7
359	Reply. <i>Hepatology</i> , 2011 , 53, 369-370	11.2	
358	Medical management of hepatorenal syndrome. 2012 , 27, 34-41		28
357	Hepatorenal syndrome: a critical update. 2012 , 33, 55-69		21
356	High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. 2012 , 24, 619-26		35

355	Recent advances in our understanding of hepatorenal syndrome. 2012 , 9, 382-91		70
354	Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis. <i>Liver International</i> , 2012 , 32, 1327-32	7.9	36
353	QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. <i>Liver International</i> , 2012 , 32, 1510-5	7.9	34
352	Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. 2012 , 56, 1047-1053		93
351	Noradrenaline in the treatment of patients with hepatorenal syndrome - back to the roots?. 2012 , 57, 925; author reply 926		1
350	The cardiorenal link in advanced cirrhosis. 2012 , 79, 53-5		50
349	[Physiopathological bases for the use of human albumin in liver cirrhosis]. 2012 , 35, 42-9		1
348	The kidney in pediatric liver transplantation: an updated perspective. 2012 , 16, 818-28		14
347	The heart: pathophysiology and clinical implications of cirrhotic cardiomyopathy. <i>Journal of the Chinese Medical Association</i> , 2012 , 75, 619-23	2.8	25
346	Postoperative troponin T elevation as a predictor of early acute kidney injury after orthotopic liver transplantation: a preliminary retrospective study. 2012 , 44, 1999-2001		5
345	Terlipressin for hepatorenal syndrome. 2012 , CD005162		61
344	Hepatorenal Syndrome. 2012 , 1, e62-e68		0
343	Acute-on chronic liver failure. 2012 , 57, 1336-48		440
342	Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1. <i>Annals of Hepatology</i> , 2012 , 11, 232-239	3.1	6
341	Revision and update on clinical practice guideline for liver cirrhosis. 2012 , 18, 1-21		97
340	Cardiovascular Complications of Cirrhosis. 2012 , 369-393		
339	Hepatorenal syndrome. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4978-84	5.6	45
338	Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. 2012 , 123, 225-39		64

337	[Cirrhotic cardiomyopathy: a specific entity]. 2012 , 61, 99-104		1
336	Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. 2012 , 59, 874-85		47
335	[Hepatorenal syndrome]. 2013 , 62, 571-82		2
334	[Hepatorenal syndrome: focus]. 2013 , 9, 471-80		1
333	Can the development of cardiac dysfunction in patients with liver cirrhosis and portal hypertension be predicted?. 2013 , 168, 1528-30		0
332	Acute on chronic liver failure: From pathophysiology to clinical management. 2013 , 3, 122-129		6
331	Liver in cardiopulmonary disease. 2013 , 27, 497-512		2
330	Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. <i>Liver International</i> , 2013 , 33, 398-409	7.9	73
329	Terlipressin for the treatment of hepatorenal syndrome in patients with cirrhosis. 2013 , 1, 241-248		1
328	Acute kidney injury in decompensated cirrhosis. 2013 , 62, 131-7		165
327	Acute kidney injury (AKI) in cirrhosis: should we change current definition and diagnostic criteria of renal failure in cirrhosis?. 2013 , 59, 415-7		28
326	New insights into cirrhotic cardiomyopathy. 2013 , 167, 1101-8		72
325	From listing to transplant: nephrologic monitoring in cirrhotic patients awaiting liver transplantation. 2013 , 45, 2672-5		1
324	Interactions of the heart and the liver. 2013 , 34, 2804-11		253
323	Plasma copeptin, a possible prognostic marker in cirrhosis. <i>Liver International</i> , 2013 , 33, 843-51	7.9	25
322	Acute kidney injury in patients with cirrhosis: perils and promise. 2013 , 11, 1550-8		46
321	LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. 2013 , 58, 51-7		101
320	Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. 2013 , 24, 172-6		51

319	Homozygous mutation in the cardiac troponin I gene: clinical heterogeneity in hypertrophic cardiomyopathy. 2013 , 168, 1530-1		9
318	Renal Failure in Cirrhosis. 2013 , 2633-2644		1
317	Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. <i>Hepatology</i> , 2013 , 58, 1732-41	11.2	100
316	Hepatorenal syndrome in the intensive care unit. 2013 , 28, 79-92		8
315	Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. <i>Liver International</i> , 2013 , 33, 16-23	7.9	49
314	Ascites. 2013 , 5, 1-116		
313	[Mexican consensus on portal hypertension]. 2013 , 78, 92-113		3
312	Relationship between systemic hemodynamics, renal dysfunction, and fluid retention in cirrhosis. <i>Clinical Liver Disease</i> , 2013 , 2, 120-122	2.2	3
311	The Serum NT-proBNP in Patients with Cirrhosis: Relationship to Cardiac Dysfunction and Liver Function. 2013 , 2, 36-42		2
310	Octreotide: a drug often used in the critical care setting but not well understood. 2013 , 144, 1937-1945		9
309	Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis. 2013 , 25, 523-30		27
308	The pathophysiology of hepatorenal syndrome. 2013 , 11, 29-35		1
307	Updates on Hepato-Renal Syndrome. 2013 , 4, 352		9
306	N-Terminal Pro-Brain Natriuretic Peptide: Prognostic Potential in End Stage Liver Cirrhosis in a Cohort Free of Heart Failure; an Egyptian Insight. 2013 , 2,		
305	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , 2013 , 5, 685-91	3.4	18
304	Impact of the severity of end-stage liver disease in cardiac structure and function. <i>Annals of Hepatology</i> , 2013 , 12, 85-91	3.1	17
303	Acute-on-chronic liver failure: a review. 2014 , 10, 295-303		29
302	Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. <i>PLoS ONE</i> , 2014 , 9, e95736	3.7	4

301	Pathophysiology, diagnosis and clinical management of hepatorenal syndrome: from classic to new drugs. 2014 , 12, 125-35		20
300	Hepato-cardiac disorders. <i>World Journal of Hepatology</i> , 2014 , 6, 41-54	3.4	82
299	New determinants of prognosis in bacterial infections in cirrhosis. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7252-9	5.6	20
298	Diastolic dysfunction characterizes cirrhotic cardiomyopathy. 2014 , 66, 649-55		17
297	Reversible non-ischaemic cardiomyopathy and left ventricular dysfunction after liver transplantation: a single-centre experience. <i>Liver International</i> , 2014 , 34, e105-10	7.9	10
296	Pre-transplant renal impairment predicts posttransplant cardiac events in patients with liver cirrhosis. <i>Transplantation</i> , 2014 , 98, 107-14	1.8	17
295	New insight into volume overload and hepatorenal syndrome in cirrhosis, "the hepatorenal reflex hypothesis". 2014 , 348, 244-8		14
294	When should the β -blocker window in cirrhosis close?. 2014 , 146, 1597-9		20
293	Systolic dysfunction and diastolic dysfunction do not influence medium-term prognosis in patients with cirrhosis. 2014 , 25, 241-6		28
292	Could serum nitrate and nitrite levels possibly predict hepatorenal syndrome in hepatitis C virus-related liver cirrhosis?. 2014 , 33, 274-80		2
291	Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. <i>Liver International</i> , 2014 , 34, 1153-63	7.9	35
290	Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: a combined retrospective and pilot study. 2014 , 59, 471-81		16
289	Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. 2014 , 39, 699-711		12
288	Human serum albumin, systemic inflammation, and cirrhosis. 2014 , 61, 396-407		250
287	Cardiac and proinflammatory markers predict prognosis in cirrhosis. <i>Liver International</i> , 2014 , 34, e19-307.9		54
286	Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. 2014 , 11, 177-86		147
285	Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. 2014 , 61, 1014-9		43
284	Prognostic Factors in Compensated and Decompensated Cirrhosis. 2014 , 13, 171-179		4

283	Cirrhotic cardiomyopathy: review of pathophysiology and treatment. 2014 , 8, 308-15		49
282	Staging for hepatocellular carcinoma: complex and confusing. 2014 , 146, 1599-602		26
281	Terlipressin versus other vasoactive drugs for hepatorenal syndrome. 2015 ,		3
280	Cardiac dysfunction in patients with cirrhosis: is the systolic component its main feature?. 2015 , 27, 660-6		9
279	Pretransplant Type 2 Hepatorenal Syndrome Is Associated With Persistently Impaired Renal Function After Liver Transplantation. <i>Transplantation</i> , 2015 , 99, 1441-6	1.8	16
278	Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. 2015 , 15, 167		39
277	Lipopolysaccharide enhanced renal vascular response to endothelin-1 through ETA overexpression in portal hypertensive rats. 2015 , 30, 199-207		10
276	Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonance reveals impaired contractile reserve in patients with cirrhotic cardiomyopathy. 2015 , 17, 61		21
275	Renal dysfunction in cirrhosis. 2015 , 31, 215-23		10
274	Arrhythmia risk in liver cirrhosis. <i>World Journal of Hepatology</i> , 2015 , 7, 662-72	3.4	37
273	Intensive care management of patients with liver disease: proceedings of a single-topic conference sponsored by the Brazilian Society of Hepatology. <i>Arquivos De Gastroenterologia</i> , 2015 , 52 Suppl 1, 55-72 ^{1,3}		6
272	Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. <i>World Journal of Gastroenterology</i> , 2015 , 21, 12125-40	5.6	38
271	Hepatorenal syndrome: outcome of response to therapy and predictors of survival. 2015 , 2015, 457613		16
270	Investigation of cardiomyopathy in children with cirrhotic and noncirrhotic portal hypertension. 2015 , 60, 177-81		13
269	Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. 2015 , 30, 969-74		32
268	Functional and morphological myocardial changes in hepatitis C virus patients with end-stage liver disease. 2015 , 50, 1135-43		2
267	Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options. 2015 , 32, 445-54		15
266	Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors?. <i>Journal of Clinical and Experimental Hepatology</i> , 2015 , 5, 273-5	4.1	1

265	A Treat-to-Target Concept to Guide the Medical Management of Hepatorenal Syndrome. 2015 , 60, 1474-81	7
264	Annual Update in Intensive Care and Emergency Medicine 2015. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2015 ,	0.2 1
263	The Use of Beta-Blockers in Advanced Cirrhosis Where Do We Stand?. 2015 , 14, 46-52	1
262	Cirrhotic cardiomyopathy. 2015 , 225-235	
261	Ascites. 2015 , 151-163	
260	Treatment and management of ascites and hepatorenal syndrome: an update. 2015 , 8, 83-100	19
259	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. 2015 , 63, 1272-84	323
258	The Treatment of Hepatorenal Syndrome. 2015 , 33, 548-54	22
257	Cirrhotic Multiorgan Syndrome. 2015 , 60, 3209-25	28
256	Pretransplantation Evaluation. 2015 , 419-440	
255	Complications of cirrhosis. A 50 years flashback. 2015 , 50, 763-80	18
254	Cirrhotic Cardiomyopathy: Pathogenic Mechanisms and Management Strategies. 2015 , 159-168	
253	Study on assessment of renal function in chronic liver disease. 2015 , 9, OC09-12	1
252	Management of cirrhotic ascites. 2015 , 6, 124-37	31
251	Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. 2015 , 47, 1052-8	12
250	The Kidney in Pediatric Liver Disease. 2015 , 17, 36	11
249	Early predictors of acute kidney injury in patients with cirrhosis and bacterial infection: urinary neutrophil gelatinase-associated lipocalin and cardiac output as reliable tools. 2015 , 34, 140-5	4
248	Recent advances in cirrhotic cardiomyopathy. 2015 , 60, 1141-51	20

247	Cardiohepatic syndrome. 2015 , 12, 68-78		27
246	Renal insufficiency in the patient with chronic liver disease. <i>Clinics in Liver Disease</i> , 2015 , 19, 45-56	4.6	12
245	Acute kidney injury and hepatorenal syndrome in cirrhosis. 2015 , 30, 236-43		32
244	[Acute Kidney Injury in Cirrhotic Patients with Portal Hypertension]. 2016 , 68, 237-244		
243	Pretransplant Left Ventricular Dysfunction Adversely Affects Perioperative Outcomes in Pediatric Liver Transplantation: A Retrospective Observational Study. 2016 , 48, 3328-3335		6
242	Portal Hypertension. 2016 , 554-566		
241	Diastolic dysfunction in cirrhosis. 2016 , 21, 599-610		20
240	The Organs in Acute-on-Chronic Liver Failure. 2016 , 36, 174-80		6
239	Acute-on-Chronic Liver Failure: Definition, Diagnosis, and Clinical Characteristics. 2016 , 36, 109-16		65
238	Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis. 2016 , 34, 382-6		48
237	Infecciones bacterianas en la cirrosis. 2016 , 12, 666-672		
236	Editorial: increased cardiac output in cirrhosis - non-invasive assessment of regional blood flow by magnetic resonance angiography. 2016 , 43, 1340-2		2
235	Non-selective β blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. 2016 , 3, e000104		8
234	Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. <i>Liver International</i> , 2016 , 36, 1304-12	7.9	50
233	Cardiac changes in pediatric liver transplant recipients: are they truly irreversible?. 2016 , 10, 390-3		
232	Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. 2016 , 10, 1153-1161		10
231	Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study. 2016 , 10, 377-85		33
230	Cardiac manifestations in alcoholic liver disease. 2016 , 92, 235-9		11

229	Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. 2016 , 67, 318-28		54
228	Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase. 2016 , 67, 125-30		53
227	Sepsis-induced acute kidney injury in patients with cirrhosis. 2016 , 10, 115-23		31
226	Cardiac imaging in patients with chronic liver disease. 2017 , 37, 347-356		10
225	Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1. 2017 , 45, 593-603		27
224	Cirrhotic cardiomyopathy: is there any correlation between the stage of cardiac impairment and the severity of liver disease?. 2017 , 12, 1283162		8
223	Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. <i>Hepatology</i> , 2017 , 65, 2019-2030	11.2	34
222	Cardiovascular Assessment of the Liver Transplantation Candidate. 2017 , 55, 42-66		6
221	Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome. 2017 , 6, CD005162		19
220	Reply. <i>Hepatology</i> , 2017 , 66, 302-303	11.2	2
219	Diagnosis and prognosis of acute on chronic liver failure (ACLF) in cirrhosis. 2017 , 66, 451-453		15
218	Terlipressin versus other vasoactive drugs for hepatorenal syndrome. 2017 , 9, CD011532		22
217	Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit?. 2017 , 92, 1058-1070		57
216	Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. 2017 , 16, 250-257		
215	Ascites. 2017 , 475-484		1
214	Ascites, refractory ascites and hyponatremia in cirrhosis. 2017 , 5, 104-112		31
213	Renal function and oxygenation are impaired early after liver transplantation despite hyperdynamic systemic circulation. 2017 , 21, 87		11
212	Cirrhotic Cardiomyopathy and Liver Transplantation. 2017 , 449-462		

211	Survival at 2 years among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass. <i>Liver International</i> , 2017 , 37, 700-706	7.9	20
210	Renin angiotensin system in liver diseases: Friend or foe?. <i>World Journal of Gastroenterology</i> , 2017 , 23, 3396-3406	5.6	52
209	Hepatorenal Syndrome. 2017 , 501-510		
208	Complications of Cirrhosis: Introduction. 2017 , 427-433		1
207	Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C. <i>Annals of Gastroenterology</i> , 2017 , 30, 675-681	2.2	2
206	Cirrhotic Cardiomyopathy: Another Case of a Successful Approach to Treatment of Hepatorenal Syndrome. 2016 , 10, 531-537		10
205	Cirrhotic Cardiomyopathy. 2017 ,		
204	βBlocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial. 2018 , 30, 930-937		18
203	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. 2018 , 69, 406-460		930
202	Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. 2018 , 30, 659-667		4
201	Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. 2018 , 33, 1333-1343		7
200	Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. 2018 , 68, 949-958		75
199	Cardiovascular Alterations in Acute and Chronic Liver Failure. 2018 , 105-119		
198	The intensive care unit course and outcome in acute-on-chronic liver failure are comparable to other populations. 2018 , 69, 803-809		23
197	Perioperative management of liver surgery-review on pathophysiology of liver disease and liver failure. 2018 , 50, 81-86		6
196	Serum adrenomedullin and urinary thromboxane B help early categorizing of acute kidney injury in decompensated cirrhotic patients: A prospective cohort study. 2018 , 48, E9-E21		2
195	Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. 2018 , 314, G275-G286		25
194	Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. 2018 , 47, 78-85		30

193 Chapter 2: Clinical Presentation of Portal Hypertension. **2018,**

192 The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. *Liver International*, **2018**, 38, 570-580 7.9 76

191 KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. **2018**, 24, 230-277 33

190 2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines for Ascites and Related Complications: What Has Been Changed from the 2011 KASL Clinical Practice Guidelines?. **2018**, 72, 179

189 EVALUATION OF THE BEHAVIOR OF LEVELS OF HMGB1 AND IL6 AS PREDICTORS OF INFECTION, ACUTE KIDNEY INJURY AND MORTALITY IN CIRRHOTIC PATIENTS WITH VARICEAL BLEEDING. *Arquivos De Gastroenterologia*, **2018**, 55, 338-342 1.3 4

188 Ascites and Hyponatremia. **2018**, 220-232.e4 0

187 9 Interventional Management of Benign Refractory Ascites. **2018,**

186 Kidney Injury and Electrolyte Abnormalities in Liver Failure. **2018**, 39, 556-565 5

185 Acute Kidney Injury and Liver Disease: Incidence, Pathophysiology, Prevention/Treatment, and Outcomes. **2018**, 113-131

184 Noradrenaline for reverting hepatorenal syndrome: a prospective, observational, single-center study. **2018**, 11, 317-324 11

183 Oliguria in critically ill patients: a narrative review. **2018**, 31, 855-862 17

182 Hepatorenal syndrome. **2018**, 4, 23 82

181 [Acute Kidney Injury and Hepatorenal Syndrome]. **2018**, 72, 64-73 2

180 Pretransplantation Cystatin C, but not Creatinine, Predicts 30-day Cardiovascular Events and Mortality in Liver Transplant Recipients With Normal Serum Creatinine Levels. **2018**, 50, 1094-1099 4

179 The relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis. **2018**, 69, 746-747 6

178 Hepatorenal syndrome in the era of acute kidney injury. *Liver International*, **2018**, 38, 1891-1901 7.9 28

177 Renal Function in Cirrhosis: A Critical Review of Available Tools. **2018**, 38, 230-241 23

176 Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study. **2018**, 48, 740-749 12

175	Intensive Care Therapy for Patients with Advanced Liver Diseases. 2018 , 34, 283-289	2
174	Renal effects of norepinephrine-induced variations in mean arterial pressure after liver transplantation: A randomized cross-over trial. 2018 , 62, 1229-1236	8
173	Portal Hypertension in Cirrhosis. 2018 , 180-208	
172	Ascites. 2018 , 127-150	
171	Urinary cell cycle arrest biomarker [TIMP-2][IGFBP7] in patients with hepatorenal syndrome. 2019 , 24, 692-699	5
170	News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. 2019 , 71, 811-822	118
169	A clinical risk prediction model to identify patients with hepatorenal syndrome at hospital admission. 2019 , 73, e13393	3
168	Arterial Blood Pressure at Liver Transplant Evaluation Predicts Renal Histology in Candidates With Renal Dysfunction. 2019 , 25, 1756-1767	6
167	Incidence and mortality of renal dysfunction in cirrhotic patients with acute gastrointestinal bleeding: a systematic review and meta-analysis. 2019 , 13, 1181-1188	7
166	Critical Care for Potential Liver Transplant Candidates. 2019 ,	
165	Acute Kidney Injury and Hepatorenal Syndrome. 2019 , 147-161	
164	Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging. 2019 , 317, G253-G263	8
163	Pathophysiology and Management of the Hepatorenal Syndrome. 2019 , 774-781.e2	
162	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. 2019 , 157, 149-162	91
161	Hepatorenal Syndrome. 2019 , 14, 774-781	35
160	Vascular syndromes in liver cirrhosis. 2019 , 12, 387-397	14
159	Development and Validation of a Scoring System That Includes Corrected QT Interval for Risk Analysis of Patients With Cirrhosis and Gastrointestinal Bleeding. 2019 , 17, 1388-1397.e1	9
158	An update on cirrhotic cardiomyopathy. 2019 , 13, 497-505	14

157	Ascites, Hyponatremia, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome. 2019 , 662-675		
156	Management and outcomes of hepatorenal syndrome at an urban academic medical center: a retrospective study. 2019 , 31, 1545-1549		3
155	Development and Validation of a Model to Predict Acute Kidney Injury in Hospitalized Patients With Cirrhosis. 2019 , 10, e00075		4
154	Cardiac Imaging in Liver Transplantation Candidates: Current Knowledge and Future Perspectives. 2019 , 8,		3
153	Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. 2019 , 9, 1-7		20
152	Reply to: "It takes two "eyes" to see in depth". 2019 , 70, 791-793		2
151	Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. 2020 , 72, 463-471		19
150	Cardiorenal Syndrome in Heart Failure. 2020 ,		1
149	Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis. 2020 , 16, 137-155		37
148	Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. 2020 , 318, G313-G321		6
147	Impaired Cardiac Reserve on Dobutamine Stress Echocardiography Predicts the Development of Hepatorenal Syndrome. <i>American Journal of Gastroenterology</i> , 2020 , 115, 388-397	0.7	14
146	Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives. <i>Liver International</i> , 2020 , 40, 2888-2905	7.9	8
145	Hepatorenal syndrome in children: a review. 2021 , 36, 2203-2215		6
144	Non-selective Beta-Blockers in Decompensated Cirrhosis. 2020 , 19, 186-196		
143	Comparison of Therapies for Secondary Prophylaxis of Esophageal Variceal Bleeding in Cirrhosis: A Network Meta-analysis of Randomized Controlled Trials. 2020 , 42, 1246-1275.e3		1
142	Evaluation of the Biomarkers HMGB1 and IL-6 as Predictors of Mortality in Cirrhotic Patients with Acute Kidney Injury. 2020 , 2020, 2867241		4
141	Associations Between Mean Arterial Pressure and Poor ICU Outcomes in Critically Ill Patients With Cirrhosis: Is 65 The Sweet Spot?. 2020 , 48, e753-e760		3
140	Hepatorenal syndrome: pathophysiology, diagnosis, and management. 2020 , 370, m2687		39

139	Evaluation of Renal Disease in Patients With Cirrhosis. 2020 , 54, 314-321			2
138	Review on Ascites in Pets. 2020 ,			0
137	Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. 2020 , 19, 1-12			4
136	Clinical Application of Kidney Biomarkers in Cirrhosis. 2020 , 76, 710-719			19
135	Pathophysiology of Portal Hypertension. 2020 , 659-669			1
134	[Paradigm shift in understanding Acute kidney injury in patients with chronic liver disease: From pathophysiology to defining disease entities]. 2020 , 58, 254-266			0
133	Short-term hemodynamic effects of β blockers influence survival of patients with decompensated cirrhosis. 2020 , 73, 829-841			16
132	Association between cardiac dysfunction, arrhythmias and chronic liver diseases: A narrative review. 2020 , 32, 4-12			
131	An Integrated Review of the Hepatorenal Syndrome. <i>Annals of Hepatology</i> , 2021 , 22, 100236	3.1		5
130	Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. 2021 , 18, 117-135			16
129	Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. 2021 , 75 Suppl 1, S36-S48			3
128	A case of cirrhotic multi-organ failure in a Caucasian dog. 2021 , 56, 27-32			
127	Advances in the Mechanism of Cytochrome P450 on Organ Transplantation. 2021 , 11, 2757-2761			
126	Ascites. 2021 , 168-178.e5			
125	Renal Dysfunction in Cirrhosis: Critical Care Management. 2021 , 25, 207-214			2
124	Association Between Serum IL-6, IL-10, IL-12, and IL-23 Levels and Severity of Liver Cirrhosis. 2021 , 75, 199-203			1
123	Acute on Chronic Liver Failure: Role of the Bacterial Infections.			
122	Management of Refractory Ascites Due to Portal Hypertension: Current Status. 2021 , 298, 493-504			3

121	Renal Hemodynamics, Function, and Oxygenation in Critically Ill Patients and after Major Surgery.. 2021 , 2, 894-904		0
120	Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. <i>Clinics in Liver Disease</i> , 2021 , 25, 441-460	4.6	0
119	Recent advances in the understanding and management of hepatorenal syndrome. 2021 , 10, 48		1
118	Treatment of Severe Acute on Chronic Liver Failure: Management of Organ Failures, Investigational Therapeutics, and the Role of Liver Transplantation. 2021 , 55, 667-676		3
117	A Review of Hepatorenal Syndrome. 2021 , 13, e16084		1
116	Acute kidney injury and hepatorenal syndrome in cirrhosis. <i>World Journal of Gastroenterology</i> , 2021 , 27, 3984-4003	5.6	2
115	The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin. 2021 , 27, 1191-1202		1
114	Management of the major complications of cirrhosis: Beyond guidelines. 2021 , 75 Suppl 1, S135-S146		6
113	Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. 2021 , 75 Suppl 1, S49-S66		25
112	Diagnosis and Management of Cirrhotic Cardiomyopathy.. <i>Journal of Clinical and Experimental Hepatology</i> , 2022 , 12, 186-199	4.1	3
111	Perioperative Evolution of Sodium Levels in Cirrhotic Patients Undergoing Liver Transplantation: An Observational Cohort and Literature Review. 2021 , 13, 71-82		
110	Current knowledge about biomarkers of acute kidney injury in liver cirrhosis. 2021 ,		1
109	Association Between Cirrhosis and 30-Day Rehospitalization After Index Hospitalization for Heart Failure. 2021 , 100993		
108	Effect of ingesting a meal and orthostasis on the regulation of splanchnic and systemic hemodynamics and the responsiveness of cardiovascular β adrenoceptors. 2021 , 321, G513-G526		0
107	Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion.. 2021 , 9, 505-520		0
106	Epidemiology of Sepsis-Associated Acute Kidney Injury in Beijing, China: A Descriptive Analysis. 2021 , 14, 5631-5649		0
105	Reply to: "Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link?". 2021 , 75, 993-994		
104	Regulation of the Extracellular Fluid Volume and Renal Function. 2011 , 239-267		4

103	Pathophysiology of Portal Hypertension. 2015 , 3631-3665		5
102	HEPATIC CIRRHOSIS. 2009 , 505-525		2
101	Hepatic Encephalopathy, Hepatorenal Syndrome, Hepatopulmonary Syndrome, and Systemic Complications of Liver Disease. 2010 , 1543-1555.e6		1
100	Acute Kidney Injury. 2012 , 1044-1099		10
99	The interplay between gastrointestinal and cardiovascular diseases: a narrative review focusing on the clinical perspective. 2021 , 32, 132-139		2
98	Prediction of Perioperative Cardiovascular Events in Liver Transplantation. <i>Transplantation</i> , 2021 , 105, 593-601	1.8	11
97	Paracentesis-induced circulatory dysfunction: are there albumin alternatives?. <i>Egyptian Liver Journal</i> , 2020 , 10,	1.6	1
96	Abnormal Expression of Urea Transporter Protein in a Rat Model of Hepatorenal Syndrome Induced by Succinylated Gelatin. <i>Medical Science Monitor</i> , 2015 , 21, 2905-11	3.2	3
95	Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial. <i>PLoS Medicine</i> , 2017 , 14, e1002248	11.6	30
94	Cardiac function in patients with early cirrhosis during maximal beta-adrenergic drive: a dobutamine stress study. <i>PLoS ONE</i> , 2014 , 9, e109179	3.7	11
93	Management of Hepatorenal Syndrome: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2020 , 8, 192-199	5.2	5
92	Poor outcomes with treatment of hepatorenal syndrome type 1 with splanchnic vasoconstrictors and albumin: report of seven cases and review of the literature. <i>Arquivos De Gastroenterologia</i> , 2009 , 46, 214-8	1.3	3
91	Clinical use of albumin in hepatology. <i>Blood Transfusion</i> , 2009 , 7, 268-77	3.6	31
90	Progress in treatment of massive ascites and hepatorenal syndrome. <i>World Journal of Gastroenterology</i> , 2006 , 12, 516-9	5.6	8
89	Cardiopulmonary complications in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2006 , 12, 526-38	5.6	46
88	Liver cirrhosis and arterial hypertension. <i>World Journal of Gastroenterology</i> , 2006 , 12, 678-85	5.6	30
87	Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. <i>World Journal of Gastroenterology</i> , 2014 , 20, 15499-517	5.6	45
86	Allocation of patients with liver cirrhosis and organ failure to intensive care: Systematic review and a proposal for clinical practice. <i>World Journal of Gastroenterology</i> , 2015 , 21, 8964-73	5.6	12

85	Cirrhotic cardiomyopathy. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11502-21	5.6	83
84	Role of vaptans in the management of hydroelectrolytic imbalance in liver cirrhosis. <i>World Journal of Hepatology</i> , 2014 , 6, 793-9	3.4	9
83	Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients. <i>World Journal of Hepatology</i> , 2015 , 7, 507-20	3.4	36
82	Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis?. <i>World Journal of Hepatology</i> , 2016 , 8, 200-6	3.4	18
81	Cardiohepatic interactions—from humoral theory to organ transplantation. <i>Arquivos Brasileiros De Cardiologia</i> , 2014 , 102, e65-7	1.2	4
80	Cardiac and renal effects of liver cirrhosis in a growing animal model. <i>Acta Cirurgica Brasileira</i> , 2021 , 36, e360806	1.6	
79	Performance of High Mobility Protein Group 1 and Interleukin-6 as Predictors of Outcomes Resulting from Variceal Bleeding in Patients with Advanced Chronic Liver Disease. <i>Inflammation</i> , 2021 , 1	5.1	0
78	Immunoparalysis in Liver Disease. <i>Yearbook of Intensive Care and Emergency Medicine</i> , 2006 , 650-660		
77	Influence of Sodium on Pulse Pressure and Systolic Hypertension in the Elderly. 2007 , 275-284		
76	Management of Hepatorenal Syndrome. 2008 , 47-57		
75	Renal Failure in Cirrhosis. 2008 , 2235-2245		
74	Pathophysiology of the Hepatorenal Syndrome. 2009 , 1040-1047		
73	Renal Function in Liver Disease. 2009 , 261-267		
72	Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome. 2009 , 859-866		
71	Dysfonctions circulatoires de la cirrhose et de l'insuffisance hépatique aiguë. 2010 , 105-115		
70	Syndrome hépatorenal. 2010 , 153-163		
69	Management of Renal Failure. 2011 , 429-451		
68	The Heart in Chronic Liver Failure. 2011 , 269-288		

67	Hepatorenal Syndrome. 2011 , 752-756		
66	Hepatorenal syndrome. 2012 , 173-182		
65	Efficacy of Vaptans for Management of Ascites in Patients with Liver Cirrhosis. <i>Korean Journal of Medicine</i> , 2012 , 82, 22	0.5	
64	Liver transplantation in patients with fulminant hepatitis. 2012 , 1689-1701.e3		
63	Disorders of Sodium Balance. 2012 , 464-539		
62	Ascites and hepatorenal syndrome. 737-744		
61	Lebererkrankungen. 2014 , 357-369		
60	Pathophysiology of Portal Hypertension. 2014 , 1-41		
59	Effect of nitric oxide pathway regulation on water/sodium balance and renal function in a rodent model of acute liver and renal failure. <i>Medical Science Monitor</i> , 2014 , 20, 1735-44	3.2	2
58	Acute and Chronic Liver Disease. 2015 , 523-550		
57	The impact of large-volume paracentesis on renal haemodynamics in cirrhotic patients with ascites. <i>The Egyptian Journal of Internal Medicine</i> , 2014 , 26, 170-175	0.5	
56	Application of the Acute Kidney Injury Network Criteria in Patients with Cirrhosis and Ascites: Benefits and Limitations. <i>Annual Update in Intensive Care and Emergency Medicine</i> , 2015 , 405-414	0.2	
55	Hepatorenales Syndrom. 2015 , 1-10		
54	Ascites and Its Complications. 2087-2106		
53	Hepatorenal Syndrome. 2017 , 531-544		
52	Liver transplantation in patients with fulminant hepatitis. 2017 , 1766-1780.e4		
51	Hepatorenal Syndrome-Current Concepts in Pathophysiology. <i>Gastroenterology & Hepatology (Bartlesville, Okla)</i> , 2017 , 7,	0.2	
50	EVALUATION AND CORRELATION OF CARDIOVASCULAR DYSFUNCTION IN NONALCOHOLIC CIRRHOTIC PATIENTS WITH ITS SEVERITY. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2017 , 6, 5200-5204	0.1	1

49 Cardiopulmonary Complications of Cirrhosis. **2018**, 281-292.e5

48 Diuretic window hypothesis in cirrhosis: Changing the point of view. *World Journal of Gastroenterology*, **2019**, 25, 3283-3290 5.6 0

47 Hepato-renal Dysfunction in a Patient with Advanced Heart Failure. **2020**, 205-218

46 Early echocardiographic signs of diastolic dysfunction predict acute kidney injury in cirrhotic patients. *Journal of the Chinese Medical Association*, **2020**, 83, 984-990 2.8 0

45 Historical Aspects of Ascites and the Hepatorenal Syndrome. *Clinical Liver Disease*, **2021**, 18, 14-27 2.2

44 Hepatorenal syndrome: A review into changing definition, diagnostic criteria, pathophysiology, and management. *CHRISMED Journal of Health and Research*, **2020**, 7, 83 0.1 0

43 Immunoparalysis in Liver Disease. **2006**, 650-660

42 Hans Popper Aware Lecture: Circulatory and renal failure in cirrhosis. 39-52

41 Hepatorenal syndrome [A defined entity with a standard treatment?]. 280-290

40 Hepatorenal syndrome in cirrhosis. **2008**, 221-232

39 Aszites und hepatorenales Syndrom. **2007**, 941-949

38 Hepatorenal syndrome. **2008**, 329-337

37 Pathophysiology Behind Cardiopulmonary Complications of Cirrhosis and Portal Hypertension. **2021**, 43-72

36 Hepatorenal syndrome. *Clinical Biochemist Reviews*, **2007**, 28, 11-7 7.3 32

35 Beta-blockers in liver cirrhosis. *Annals of Gastroenterology*, **2014**, 27, 20-26 2.2 24

34 Cardiovascular dysfunction in patients with liver cirrhosis. *Annals of Gastroenterology*, **2015**, 28, 31-40 2.2 62

33 Hyponatremia and Hepatorenal Syndrome. *Gastroenterology and Hepatology*, **2015**, 11, 220-9 0.7 5

32 Q-T Interval Prolongation in Patients with Liver Cirrhosis. *Current Health Sciences Journal*, **2018**, 44, 274-279 1

31	A Prospective Study of Prevalence and Predictors of Cirrhotic Cardiomyopathy and its role in development of Hepatorenal Syndrome. <i>Journal of Clinical and Experimental Hepatology</i> , 2021 ,	4.1	
30	Cirrhotic Cardiomyopathy - A Veiled Threat. <i>Cardiology in Review</i> , 2020 ,	3.2	0
29	Non-selective beta-blockers in patients with ascites: the complex interplay among the liver, kidney, and heart.. <i>Liver International</i> , 2022 ,	7.9	4
28	Hepatorenal Syndrome: Pathophysiology.. <i>Clinics in Liver Disease</i> , 2022 , 26, 165-179	4.6	0
27	Development of the AI-Cirrhosis-ECG (ACE) Score: An electrocardiogram-based deep learning model in cirrhosis.. <i>American Journal of Gastroenterology</i> , 2021 , 117,	0.7	1
26	Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy. 2022 , 2,		1
25	Impact of cardiac dysfunction on morbidity and mortality in liver transplant candidates.. <i>Clinical Transplantation</i> , 2022 , e14682	3.8	1
24	Impact of liver cirrhosis on ST-elevation myocardial infarction related shock and interventional management, a nationwide analysis. <i>World Journal of Hepatology</i> , 2022 , 14, 766-777	3.4	
23	Update on hepatorenal Syndrome: Definition, Pathogenesis, and management.. <i>Arab Journal of Gastroenterology</i> , 2022 ,	1.7	0
22	Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications).. <i>Clinical Drug Investigation</i> , 2022 , 1	3.2	0
21	POSITION STATEMENT ON THE USE OF ALBUMIN IN LIVER CIRRHOSIS.. <i>Annals of Hepatology</i> , 2022 , 100708	3.08	0
20	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022 , 100513	10.3	1
19	The Cardio-Renal Connection s Cardiac Output the Sole Determinant of Renal Dysfunction in Cirrhosis?. <i>American Journal of Gastroenterology</i> , 2022 , Publish Ahead of Print,	0.7	
18	Cardiovascular mapping in cirrhosis from the compensated stage to hepatorenal syndrome: a magnetic resonance study. <i>American Journal of Gastroenterology</i> , 2022 , Publish Ahead of Print,	0.7	1
17	Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart. 2022 ,		
16	Invasive hemodynamic parameters in patients with hepatorenal syndrome. 2022 , 42, 101094		
15	Prevention of Further Decompensation in Patients With Ascites. 2022 , 549-562		0
14	Prognostic Implications of Systolic Function in Patients with Cirrhosis. 2022 ,		0

- 13 Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review. **2022**, 101509 1
- 12 Organ Crosstalk in Acute Kidney Injury: Evidence and Mechanisms. **2022**, 11, 6637 1
- 11 Hepatorenal Syndrome. **2022**, 107-122 0
- 10 Diuretic resistance in patients with kidney disease: Challenges and opportunities. **2023**, 157, 114058 0
- 9 HFA-PEFF score as an independent predictor of 2-year mortality in liver cirrhosis patients. **2023**, 35, 204-211 0
- 8 Cirrhotic cardiomyopathy. **2023**, 217-246 0
- 7 Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1. **2023**, Publish Ahead of Print, 0
- 6 Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?. 9, 0
- 5 Hepatorenal syndrome and acute kidney injury in cirrhosis. **2023**, 275-291 0
- 4 Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats. **2023**, 11, 607 0
- 3 Acute Kidney Injury in Patients with Cirrhosis. **2023**, 388, 733-745 0
- 2 Hepatorenal Syndrome and Other Liver-Related Kidney Diseases. **2018**, 290-298.e2 0
- 1 Cirrhotic cardiomyopathy: Predictors of major adverse cardiac events and assessment of reversibility after liver transplant. **2023**, 0